Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Russian HIV initiatives get further $24m

This article was originally published in Clinica

Executive Summary

A Russian HIV/AIDS programme that has been built up over the last five years with the support of an $89m grant from the Global Fund to Fight AIDS, Tuberculosis and Malaria has received the funding needed to operate for a further two years. The Global Fund has approved an additional $24m to fund the programme until the end of 2011. The prevention programme, described by the Global Fund as "successful", is targeted at "highly vulnerable" groups, and runs across the country's 83 administrative regions. An estimated 1 million people are infected with HIV in Russia. The government has contributed $226m to the Global Fund, and supports other initiatives nationally.

You may also be interested in...



COVID-19: ResMed Ramps Up CPAP, BPAP Manufacturing To Address Ventilator Shortage

ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage. 

Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

Topics

UsernamePublicRestriction

Register

MT044815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel